CA3094215A1 - Galectin-10 antibodies - Google Patents

Galectin-10 antibodies Download PDF

Info

Publication number
CA3094215A1
CA3094215A1 CA3094215A CA3094215A CA3094215A1 CA 3094215 A1 CA3094215 A1 CA 3094215A1 CA 3094215 A CA3094215 A CA 3094215A CA 3094215 A CA3094215 A CA 3094215A CA 3094215 A1 CA3094215 A1 CA 3094215A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
galectin
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3094215A
Other languages
English (en)
French (fr)
Inventor
Bart Lambrecht
Savvas SAVVIDES
Hamida HAMMAD
Kenneth VERSTRAETE
Jean-Michel PERCIER
Christophe Blanchetot
Michael Saunders
Hans De Haard
Bas Van der Woning
Emma PERSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
ArgenX BVBA
Original Assignee
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1806099.6A external-priority patent/GB201806099D0/en
Priority claimed from GBGB1901648.4A external-priority patent/GB201901648D0/en
Application filed by Universiteit Gent, Vlaams Instituut voor Biotechnologie VIB, ArgenX BVBA filed Critical Universiteit Gent
Publication of CA3094215A1 publication Critical patent/CA3094215A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3094215A 2018-04-13 2019-04-12 Galectin-10 antibodies Pending CA3094215A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1806099.6A GB201806099D0 (en) 2018-04-13 2018-04-13 Galectin-10 Antibodies
GB1806099.6 2018-04-13
GBGB1901648.4A GB201901648D0 (en) 2019-02-06 2019-02-06 Galectin-10 antibodies
GB1901648.4 2019-02-06
PCT/EP2019/059570 WO2019197675A1 (en) 2018-04-13 2019-04-12 Galectin-10 antibodies

Publications (1)

Publication Number Publication Date
CA3094215A1 true CA3094215A1 (en) 2019-10-17

Family

ID=66240109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3094215A Pending CA3094215A1 (en) 2018-04-13 2019-04-12 Galectin-10 antibodies

Country Status (12)

Country Link
US (3) US11066473B2 (https=)
EP (1) EP3774905A1 (https=)
JP (1) JP2021520825A (https=)
KR (1) KR20210005070A (https=)
CN (1) CN112166126A (https=)
AU (1) AU2019250689A1 (https=)
BR (1) BR112020020868A2 (https=)
CA (1) CA3094215A1 (https=)
IL (1) IL278010A (https=)
MX (1) MX2020010821A (https=)
SG (1) SG11202009140SA (https=)
WO (1) WO2019197675A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.
US11860114B2 (en) * 2020-03-26 2024-01-02 David Hurwitz Determining atomic coordinates from X-ray diffraction data
WO2021223079A1 (zh) * 2020-05-06 2021-11-11 科稷达隆(北京)生物技术有限公司 一种纳米抗体及其应用
CN113666999B (zh) * 2021-08-31 2022-08-19 中国医学科学院基础医学研究所 用于治疗2型免疫疾病的多肽
CN113667000B (zh) * 2021-08-31 2022-08-19 中国医学科学院基础医学研究所 多肽在制备治疗2型免疫疾病的药物中的应用
CN113999287B (zh) * 2021-12-02 2023-06-27 深圳湾实验室坪山生物医药研发转化中心 一种靶向半乳糖凝集素-10的多肽抑制剂及其制备方法和用途
IL314367A (en) 2022-01-18 2024-09-01 argenx BV Antibodies to galectin 10
KR20240133723A (ko) 2022-01-18 2024-09-04 아르제넥스 비브이 Fab 단편의 분무화
WO2023150260A2 (en) * 2022-02-03 2023-08-10 Regents Of The University Of Minnesota Compounds that target tem8, compositions, and methods
JPWO2023153496A1 (https=) * 2022-02-10 2023-08-17
CN115785245A (zh) * 2022-07-18 2023-03-14 上海博满生物科技有限公司 一种半乳糖凝集素10晶体及其制备的抗体IgY和药物制剂
CN115902204A (zh) * 2022-09-23 2023-04-04 北京大学第三医院（北京大学第三临床医学院） 一种外泌体形式半乳糖凝集素9的检测方法与试剂盒
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE10333406A1 (de) * 2003-07-15 2005-02-10 Protagen Ag T-regulatorische-Zellen enthaltend Galectine zur Therapie und Diagnose von Erkrankungen
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
CN106645752B (zh) * 2016-12-27 2018-02-16 中南大学湘雅医院 Galectin‑10及其特异性抗体在制备检测鼻咽癌试剂盒中的应用
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Also Published As

Publication number Publication date
SG11202009140SA (en) 2020-10-29
EP3774905A1 (en) 2021-02-17
JP2021520825A (ja) 2021-08-26
WO2019197675A1 (en) 2019-10-17
MX2020010821A (es) 2021-01-15
US11713354B2 (en) 2023-08-01
US20240026010A1 (en) 2024-01-25
CN112166126A (zh) 2021-01-01
US11066473B2 (en) 2021-07-20
KR20210005070A (ko) 2021-01-13
US20190367619A1 (en) 2019-12-05
BR112020020868A2 (pt) 2021-04-06
US20210332140A1 (en) 2021-10-28
AU2019250689A1 (en) 2020-10-08
IL278010A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
US11713354B2 (en) Galectin-10 antibodies
JP6345800B2 (ja) 抗体−フィノマー複合体
JP6783754B2 (ja) 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
TWI790370B (zh) 抗trem-1抗體及其用途
US10696741B2 (en) Anti-IL-22R antibodies
CN111630065A (zh) 抗c5抗体组合及其用途
KR20240049265A (ko) 인간 피브린 또는 피브리노겐 γC 도메인에 결합하는 항체 및 사용 방법
JP2024518724A (ja) 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途
KR20250150541A (ko) 인터류킨 4 수용체 알파에 결합하는 항체 및 사용 방법
US20250059285A1 (en) Galectin-10 antibodies
KR20230087552A (ko) Cd45를 다량체화하는 결합 분자
EA047651B1 (ru) Антитела против галектина-10
JP7735545B2 (ja) Ｃｄｃプラットホーム抗体
HK40034251A (en) Galectin-10 antibodies
US20260008855A1 (en) Klrb1 binding agents and methods of use thereof
JP2017057201A (ja) 抗体−フィノマー複合体を含む医薬組成物
TW202523697A (zh) 抗ｔｓｌｐ抗體構築體及其用途
JP2026514143A (ja) Ｏｘ４０ｌに結合する抗体及びその使用方法
EA051360B1 (ru) Фармацевтическая композиция антитела к il4r и ее применение
EA046142B1 (ru) Антитела к trem-1 и их применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220223

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240903

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250929

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251201